Skip to content
Sign in
StableHealthReported 2026-11-19 08:00

Ionis and Otsuka's ulefnersen meets primary endpoint in FUS-ALS phase 3 trial

The phase 3 FUSION trial met its primary endpoint, showing a statistically significant improvement in a combined measure of function and survival for FUS-ALS patients treated with ulefnersen versus placebo. This is the first placebo-controlled ALS trial targeting a genetic cause to meet its primary endpoint.

Why it matters. Patients with FUS-ALS, a rare and aggressive form of ALS, now have a potential first-in-class therapy targeting the underlying genetic mutation, offering a meaningful advance in treatment options for a historically underserved patient…

01

Evidence

  • MMedical XpressMedia2026-11-19 08:00
    View source